ADMA Biologics (NASDAQ:ADMA) Given “Neutral” Rating at Cantor Fitzgerald

ADMA Biologics (NASDAQ:ADMA)‘s stock had its “neutral” rating restated by analysts at Cantor Fitzgerald in a research note issued to investors on Thursday,Benzinga reports.

Other research analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Wall Street Zen raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, ADMA Biologics currently has an average rating of “Buy” and an average target price of $32.00.

ADMA Biologics Trading Down 15.0%

ADMA Biologics stock opened at $9.63 on Thursday. The company has a market cap of $2.29 billion, a price-to-earnings ratio of 16.05 and a beta of 0.51. The firm has a 50-day moving average of $15.95 and a 200-day moving average of $16.52. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. ADMA Biologics has a one year low of $8.62 and a one year high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million for the quarter, compared to the consensus estimate of $139.80 million. During the same quarter in the previous year, the business earned $0.46 earnings per share. ADMA Biologics’s quarterly revenue was up 18.4% on a year-over-year basis. On average, equities analysts expect that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

Insider Transactions at ADMA Biologics

In other news, Director Steve Elms bought 7,000 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was acquired at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the purchase, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the transaction, the chief operating officer owned 466,600 shares of the company’s stock, valued at $7,292,958. The trade was a 2.12% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ADMA. Thrivent Financial for Lutherans lifted its holdings in ADMA Biologics by 24.9% during the 3rd quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock valued at $60,719,000 after purchasing an additional 826,415 shares during the last quarter. Ranger Investment Management L.P. increased its holdings in shares of ADMA Biologics by 49.1% in the second quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock valued at $43,529,000 after purchasing an additional 786,865 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in shares of ADMA Biologics in the third quarter valued at $11,334,000. American Century Companies Inc. raised its position in shares of ADMA Biologics by 1.8% in the third quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock valued at $68,842,000 after purchasing an additional 84,934 shares during the period. Finally, WINTON GROUP Ltd raised its position in shares of ADMA Biologics by 302.8% in the second quarter. WINTON GROUP Ltd now owns 272,817 shares of the biotechnology company’s stock valued at $4,968,000 after purchasing an additional 205,094 shares during the period. 75.68% of the stock is currently owned by institutional investors.

Trending Headlines about ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: ADMA was added to the Zacks Rank #1 (Strong Buy) list, which could attract buying interest and analyst attention. New Strong Buy Stocks for March 25th
• Positive Sentiment: Management and the Board publicly rejected the short‑seller report as misleading and said they are reviewing the assertions — a formal rebuttal can limit some downside if it calms investors or leads to clarifying disclosures. ADMA Biologics Addresses Misleading Short‑Seller Report
• Neutral Sentiment: Technical analysts note heavy selling has pushed ADMA into oversold territory and some see the stock set up for a rebound if selling abates and fundamentals hold. Down 27% in 4 Weeks — Turnaround Case
• Negative Sentiment: A detailed short‑seller report (Culper Research) prompted a sharp share decline and increased volatility; such reports can materially pressure price even if later disputed. Shares Plunge on Short‑Seller Allegations
• Negative Sentiment: Multiple law firms have opened securities‑fraud/shareholder investigations and issued alerts; active class‑action/claim activity increases legal and disclosure risk and can keep downward pressure on the stock. Securities‑Fraud Investigation Announced
• Negative Sentiment: Reported short interest jumped materially (recent filings show ~25.8M shares short, ~11% of float), creating added downside via short selling and raising the risk of continued volatility. ADMA Stock Slides — Facts Before You Trade

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.